Literature DB >> 9690520

Etoposide and cisplatin induced apoptosis in activated RAW 264.7 macrophages is attenuated by cAMP-induced gene expression.

A von Knethen1, A Lotero, B Brüne.   

Abstract

Previous observations suggest expression of cyclooxygenase-2 to convey macrophage protection towards apoptotic cell death. We reasoned prostaglandin formation and in turn a cAMP increase as the underlying protective principle. Here we report that exposure of macrophages to lipopolysaccharide/interferon-gamma or lipophilic cAMP analogs such as dibutyryl-cAMP or 8-bromo-cAMP for 15 h attenuated DNA fragmentation and accumulation of the tumor suppressor p53 in response to the chemotherapeutic agents cisplatin and etoposide, compared to cells that received chemotherapeutic agents only. In contrast, a 1 h lasting preexposure period revealed no protection. The demand for a long incubation period with cAMP-derivates implied cAMP-mediated gene activation as the underlying principle. Therefore, we treated cells with oligonucleotides containing a cAMP-response element (CRE) binding site. Using this decoy-approach we scavaged activated cAMP response element binding protein prior to its promoter activating ability. Incubating macrophages with decoy, but not with control oligonucleotides, reduced cAMP evoked protection and simultaneously restored p53 accumulation in response to chemotherapeutic agents. Our studies demonstrate that cAMP-initiated gene activation regulates the sensitivity towards DNA damaging agents via inhibition of a p53 dependent pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690520     DOI: 10.1038/sj.onc.1201926

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  Control of apoptosis of cardiovascular fibroblasts: a novel drug target.

Authors:  H Rupp; B Maisch
Journal:  Herz       Date:  1999-05       Impact factor: 1.443

2.  Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.

Authors:  X Fang; S X Yu; Y Lu; R C Bast; J R Woodgett; G B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 3.  Therapeutic applications of transcription factor decoy oligonucleotides.

Authors:  M J Mann; V J Dzau
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

4.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response.

Authors:  Robert A Mitchell; Hong Liao; Jason Chesney; Gunter Fingerle-Rowson; John Baugh; John David; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

5.  Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family.

Authors:  D Jean; M Bar-Eli
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

6.  Attenuation of macrophage apoptosis by the cAMP-signaling system.

Authors:  A von Knethen; B Brüne
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 7.  CRE-decoy oligonucleotide-inhibition of gene expression and tumor growth.

Authors:  Y S Cho-Chung; Y G Park; M Nesterova; Y N Lee; Y S Cho
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

8.  CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal.

Authors:  W Chen; Y L Yu; S F Lee; Y J Chiang; J R Chao; J H Huang; J H Chiong; C J Huang; M Z Lai; H F Yang-Yen; J J Yen
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

9.  Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study.

Authors:  Tayfun Dalbasti; Nezih Oktar; Sedat Cagli; Nurcan Ozdamar
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

10.  NF-kappaB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages.

Authors:  A von Knethen; D Callsen; B Brüne
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.